| Old Articles: <Older 6931-6940 Newer> |
|---|
 |
The Motley Fool
December 3, 2010
Brian Orelli |
Merck Smartens Up The acquisition of SmartCells looks like an intelligent move.   |
The Motley Fool
December 3, 2010
Seth Jayson |
How Boston Scientific May Be Failing You With recent TTM margins all well below historical averages, Boston Scientific has some work to do. |
The Motley Fool
December 2, 2010
Brian Orelli |
An Ounce of Prevention Gets Shot Down An FDA panel shoots down Merck's and Glaxo's prostate drugs. |
The Motley Fool
December 2, 2010
Brian Orelli |
A Short FDA Delay. For What? GlaxoSmithKline and Valeant aren't saying. |
The Motley Fool
December 1, 2010
Andrew Sullivan |
A Tale of 2 Stocks For slow growth industries, it's best to think about the investment in terms of what sort of return you're getting. With this in mind let's compare Landauer to L-3. |
The Motley Fool
December 1, 2010
Brian Orelli |
We're Still Buying. Probably. Despite manufacturing problems, Johnson &Johnson continues with its purchase of Crucell. |
The Motley Fool
November 30, 2010
Brian Orelli |
Better Buy: Exact Sciences or Sequenom? A battle of the diagnostic test makers. |
The Motley Fool
November 30, 2010
Jim Roya |
Here's Why I Haven't Purchased This Stock Today, I picked up shares of Sabra Health Care REIT. It's a growing small cap focused on leasing health-care facilities but now leases exclusively to former parent Sun Healthcare. |
The Motley Fool
November 30, 2010
Travis Hoium |
Simcere Pharmaceutical Group Shares Popped: What You Need to Know Shares of Chinese drug company Simcere Pharmaceutical Group jumped 13% today after the company announced a fine at a company where it has controlling interest. |
The Motley Fool
November 30, 2010
Brian Orelli |
Soros Is Buying Health Care. Should You? Some but not all of his picks look good to me. |
| <Older 6931-6940 Newer> Return to current articles. |
